

Based on the detailed analysis of the provided "LUPIN.NS" report (Simulated Date: January 17, 2026), here is the assessment for a positional trade.

Step 1: Audit the Data

- * **Data Present:**
 - * **Price Structure:** Daily (3-year) and Weekly charts, Candlestick patterns.
 - * **Trend Indicators:** EMA (20, 50, 200), Supertrend, MACD.
 - * **Momentum/Volatility:** RSI, Bollinger Bands (%B, Bandwidth), Volatility Squeeze/ATR.
 - * **Fundamentals:** Revenue/Net Income growth trends, Valuation snapshots.
 - * **Relative Strength:** RS Score, RS vs. Benchmark (CNXPHARMA).
- * **Data Missing:**
 - * **Order Flow:** No Level 2 data or market depth to judge immediate liquidity at resistance.
 - * **Fibonacci Retracement:** Specific retracement levels from the 2024-2025 highs are not drawn, though they can be visually estimated.
- * **Confidence Level:** **High**. The report provides a comprehensive technical and fundamental view, allowing for a high-probability assessment.

Step 2: Analyze the Setup

- * **Price Structure & Trend:**
 - * **Primary Trend:** The stock is in a confirmed **Strong **Uptrend****. Price is trading above the 20, 50, and 200 EMAs (Page 6).
 - * **Support:** Strong confluence of support around 2095-2144 (EMA 50 and EMA 20).
- * **Momentum & Confluence:**
 - * **The Trigger:** The most critical signal is on **Page 14/15**, showing a **"BB Squeeze + ATR Contraction"** identified on 2026-01-16. This indicates a release of pent-up energy, often leading to a sustained directional move.
 - * **Oscillators:** RSI is at 60.23 (Page 16), which is in the "sweet spot"-bullish but not yet overbought (70+).
 - * **Conflict (Caution):** The Relative Strength (RS) score is 54/100, and the classification is "Weakening Leader" (Page 4). The stock is currently underperforming the Pharma index (Page 5). Additionally, MACD shows "Momentum Weakening" with a bearish divergence detected in early January.
- * **Conclusion on Setup:**
 - * This is a **Volatility Contraction Breakout** setup within a primary uptrend. While the relative strength is currently lagging, the fresh volatility squeeze breakout often precedes a catch-up phase where the stock accelerates. The fundamentals (Growing Revenue/Income) support a bullish thesis.

Step 3: Formulate the Recommendation

Verdict: **YES**

The setup is valid for a positional entry based on the Volatility Squeeze breakout and the preservation of the primary uptrend (Price > EMA 50).*

Trade Parameters:

- * **Entry Price:** **INR 2178 - INR 2190** (Current Market Price range).
 - * **Rationale:** Entering immediately on the heels of the Jan 16th "Squeeze Breakout" signal.
- * **Stop Loss:** **INR 2085** (Hard Stop).
 - * **Rationale:** This places risk just below the **Supertrend support (2097.6)** and the **EMA 50 (2095)**. A close

below these levels invalidates the intermediate uptrend thesis. This represents roughly 4.2% risk.

* **Take Profit:** **INR 2395 - INR 2450**.

* *Rationale:*

* **Target 1 (INR 2395):** Retest of the major resistance/highs seen in late 2024/early 2025 (visible on Page 2). This offers ~10% upside.

* **Target 2 (INR 2500):** If momentum accelerates into price discovery (blue sky territory), 15% upside is the secondary target.

Risk Management Note:

Since the RS Score is low (54), this stock may move slower than the sector leaders. If the stock fails to clear the Upper Bollinger Band (**INR 2223**) within 5 trading sessions, consider tightening the stop loss to breakeven.

News & Analyst Targets

As an investment firm stock research analyst, I have compiled the latest research and developments for **Lupin Limited** for the week ending **January 17, 2026**.

1) Latest News for LUPIN (Week of Jan 11 - Jan 17, 2026)

* **Postal Ballot for Board Appointment:** On **January 14-15, 2026**, Lupin issued a Postal Ballot Notice to shareholders seeking approval for the appointment of **Mr. Anand Kripalu** as an Independent Director. This follows his nomination to the board earlier in the month, signaling a move to strengthen corporate governance.

* **Stock Performance:** The stock has seen volatility this week, trading around **INR 2,177** (NSE) as of the close on January 16. While it posted a solid ~3.5% gain for the prior week (ending Jan 9), it has seen some profit-booking in recent sessions amidst broader sector weakness.

* **Strategic Licensing Deal (Context):** Investors continue to digest the positive impact of Lupin's exclusive licensing agreement with **Gan & Lee Pharmaceuticals** (announced late Dec/early Jan). This deal gives Lupin rights to commercialize a novel **GLP-1 receptor agonist** in India, directly targeting the high-growth diabetes and obesity market.

* **Acquisition Update:** The company recently provided updates regarding the timeline for closing its acquisition of **VISUfarma B.V.**, a strategic move to expand its presence in the European ophthalmic market.

2) Brokerage Upgrades & Downgrades

There have been no *major* new brokerage rating changes specifically released this week (Jan 11-17, 2026). However, the stock maintains a **positive consensus** from the analyst community following a strong Q2 performance and updated guidance.

* **Consensus View:** The consensus rating is **"Outperform" / "Buy"**, with an average 12-month price target of approximately **INR 2,302**.

* **Recent Activity:**

* **CLSA** and **Investec** recently upgraded the stock (late 2025), citing margin expansion and the US product pipeline.

* **JPMorgan** remains one of the most bullish brokers, maintaining an "Overweight" stance.

* **Bank of America (BofA)** maintains a "Neutral" stance, acknowledging improvements but watching for consistent execution.

3) Other News Impacting LUPIN (Direct & Indirect)

* **Regulatory Headwinds (Pithampur Unit-2):** A critical factor weighing on sentiment is the **Official Action Indicated (OAI)** status classified by the US FDA for the **Pithampur Unit-2** facility. While the inspection occurred earlier (July 2025), the OAI classification (confirmed Oct 2025) remains a key risk factor being monitored in January 2026, as it can delay new product approvals from this site.

* **Sector Outlook (Q3 Earnings Preview):** The Indian pharmaceutical sector is entering the Q3 FY26 earnings

season. Analysts expect a **mixed quarter** for the sector due to pricing erosion in US generics. However, Lupin is projected to be an **outperformer**, with expectations of strong margins (22-23%) driven by niche launches like *gSpiriva* and *Tolvaptan*.

* **US Generics Market:** Competitive intensity in the US generics market (specifically for complex injectables and respiratory products) remains a key indirect variable affecting Lupin's forward guidance.

4) Latest Analyst Targets for LUPIN

The following table summarizes the most recent active price targets and ratings from major brokerage firms.

Brokerage Firm	Rating / Action	Target Price (INR)	Outlook / Key Rationale
:--- :--- :--- :---			
JPMorgan **Overweight** **INR 2,600** Bullish	on margin expansion and complex pipeline execution in the US.		
CLSA **Outperform** **INR 2,400** Upgraded recently; cites strong US sales traction and improved EBITDA margins.			
Investec **Buy** **INR 2,265** Positive on India business growth and GLP-1 opportunity; valuations seen as reasonable..			
Sharekhan **Buy** **INR 2,400** Expects continued earnings momentum from niche US launches.			
Axis Securities **Overweight** **INR 2,500 - INR 2,600** Sees upside potential driven by chronic therapy leadership in India.			
BofA Securities **Neutral** **INR 2,030** Cautious optimism; acknowledges better margins but awaits sustained consistency.			
Consensus BUY			
		~INR 2,302 *Average of all major analyst targets active as of Jan 17, 2026.*	

***Disclaimer:** Market data and analyst ratings are subject to change. Please conduct your own due diligence before making investment decisions.*


Stock Detailed Analysis Report

LUPIN.NS

Current Price: ₹2177.90

Generated: 2026-01-17 18:01

LUPIN.NS - 3 Year Daily Price Chart



Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	Yes	12.90%	11.08%

Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	10.81%	2.93%
Net Income	Yes	57.80%	13.71%
ROE	No	-17.62%	-17.62%
EPS	Yes	0.27%	3.32%

LUPIN.NS - Relative Strength Analysis

== OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	Weakening Leader
RS Score:	54.5/100
:	

== RS RATIOS ==:

1M RS:	1.054 [Leader]
3M RS:	1.114 [Leader]
6M RS:	1.130 [Leader]
1Y RS:	1.053 [Leader]
:	


== TURNAROUND ANALYSIS ==:

Turnaround Status:	Not Detected
:	


SIGNAL CRITERIA::

✗ Emerging RS:	Not accelerating
✗ Medium-term Lagging:	Not lagging
✗ Performance Improving:	Not improving


Relative Strength Analysis: LUPIN.NS vs ^CNXPHARMA
Classification: Weakening Leader
Price Performance Comparison (Normalized)



RS Ratio Trends (Multiple Timeframes)




RS Composite Score Timeline



LUPIN.NS - EMA Crossover Summary

EMA 20:	2144.05
EMA 50:	2095.10
EMA 200:	2015.07
Trend Status:	Strong Uptrend
Golden Cross Date:	2025-11-13 00:00:00+05:30
Golden Cross Price:	2052.90

LUPIN.NS EMA Crossover Analysis



LUPIN.NS - Bollinger Bands Summary

Current Price:	2177.90
Upper Band:	2223.54
Middle Band (SMA 20):	2136.70
Lower Band:	2049.87
%B:	0.7372
Band Width:	0.0813
Status:	Upper Half
Signal:	None
Recent Signal 1:	Sell Signal at 2025-11-17 00:00:00+05:30

LUPIN.NS Bollinger Bands (20, 2) Analysis




LUPIN.NS - Supertrend Summary

Status: UPTREND (Buy)

Supertrend Value: 2097.60

Signal Identified On: 2025-11-12


Supertrend Analysis for LUPIN.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




LUPIN.NS - MACD Summary

MACD Line:	29.98
Signal Line:	26.07
Histogram:	3.91
Trend:	Bullish
Momentum:	Weakening
Signal:	None
Divergences Detected:	1
└ Bearish Divergence:	Date: 2026-01-07 00:00:00+05:30, Price: 2214.30

LUPIN.NS Price






LUPIN.NS MACD (12, 26, 9)



LUPIN.NS - Volatility Squeeze Summary

BB Width:	0.0813
ATR:	46.6000
Total Signals:	43
Signal 1:	BB Squeeze + ATR Contraction at 2025-12-31 00:00:00+05:30 (Pr)
Signal 2:	BB Squeeze + ATR Contraction at 2026-01-01 00:00:00+05:30 (Pr)
Signal 3:	BB Squeeze + ATR Contraction at 2026-01-02 00:00:00+05:30 (Pr)
Signal 4:	BB Squeeze + ATR Contraction at 2026-01-05 00:00:00+05:30 (Pr)
Signal 5:	BB Squeeze + ATR Contraction (Bullish Breakout) at 2026-01-06 00:00:00+05:30 (Pr)


LUPIN.NS - Volatility Squeeze Analysis



LUPIN.NS - RSI-Volume Summary

Current RSI:	60.23
Current Volume:	1011431
Volume MA 20:	757350
Bullish Divergences:	0
Bearish Divergences:	3
Bearish Div 1:	Date: 2025-04-28 00:00:00+05:30, Price: 2092.39
Bearish Div 2:	Date: 2025-12-22 00:00:00+05:30, Price: 2126.30

LUPIN.NS RSI-Volume Divergence Analysis



LUPIN.NS - Volume Analysis

== VOLUME ANALYSIS ==:

Status: 120 Signals Detected

:

2025-12-30 [-]: Distribution Day



2026-01-08 [-]: Distribution Day

2026-01-09 [-]: Distribution Day

2026-01-13 [-]: Distribution Day

2026-01-16 [-]: Distribution Day

LUPIN.NS - Volume Analysis



Multi-Timeframe Supertrend Analysis

Timeframe	Status	Value	Last Price	Signal Date
1 Week	UPTREND (Buy)	2025.98	2177.9	2025-12-01
1 Day	UPTREND (Buy)	2097.6	2177.9	2025-11-12
15 Min	DOWNTREND (Sell)	2195.69	2175.5	2026-01-16

Multi-Timeframe MACD Analysis

Timeframe	Trend	Momentum	Signal
1 Week	Bullish	Weakening	No Signal
1 Day	Bullish	Weakening	No Signal
15 Min	Bearish	Weakening	No Signal

LUPIN.NS - 1 Week (Candlestick + EMAs)



LUPIN.NS - 1 Day (Candlestick + EMAs)



LUPIN.NS - 15 Min (Candlestick + EMAs)



Trendlyne Snapshot - LUPIN_main

Markets STARFOLIO Alerts F&O MF Reports Screeners [Subscribe](#) Superstars Portfolio Watchlist Insider Trades Results Data Downloader More ▾

Search Stock, IPO, MF A

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / [LUPIN LTD.](#)

Lupin Ltd.

NSE: LUPIN | BSE: 500257
Lupin Live Share Price Today, Share Analysis and Chart

Strong Performer, Getting Expensive In 1 Starfolio Basket

2177.90 -18.00 (-0.82%)
↑ Near 52W High of ₹2226.30

1.0M NSE+BSE Volume
NSE 16 Jan, 2026 3:31 PM (IST)

Watchlist Portfolio Alert My Notes **TRADE STOCK**

Overview FORECASTER STOCK REPORT Buy Sell Zone F&O Financials News ▾ Reports Technicals ▾ Shareholding ▾ Deals ▾ Corporate Actions ▾ Alerts About

Durability score 75.0 /100 High Financial Strength	Valuation Score 42.7 /100 Mid Valuation	Momentum Score 65.6 /100 Technically Moderately Bullish	Analyst Price Target 2,302 1Yr Price target upside is 6%
--	---	---	--

Strong Performer, Getting Expensive These stocks are strong in quality and technicals but have medium valuation. At somewhat expensive v... [View Similar](#) Embed DVM

Check Before You Buy [VIEW FULL CHECKLIST](#)
High rank **18** Positive * **5** Negative
78.3% Pass in checklist

PE Valuation Check
Right Now Undervalued **129%**
1 Year Forward Undervalued **136.2%**
INSIGHT High 5Yr PE Avg of 52.7 may distort upside values.

Lupin Key Metrics

ROE Ann. % 19.1 High in industry	Broker Average Target 6.89% upside	Market Capitalization 2,328 High in industry	Price to Book 99,486.2 Above Industry Median
--	---	--	--

Preset Metrics Preset Metrics ▾

DVM
Key Metrics
Price Chart
Forecaster
Financials
Technicals
Shareholding
Deals
Documents
Corporate actions
Company Profile X

Trendlyne Snapshot - LUPIN_forecaster

Markets STARFOLIO Alerts F&O MF Reports Screeners [Subscribe](#) Superstars Portfolio Watchlist Insider Trades Results Data Downloader More [More](#)

Search Stock, IPO, MF [India](#) [A](#)

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / [LUPIN LTD.](#)

Lupin Ltd. [ⓘ](#)

NSE: LUPIN | BSE: 500257

■ ■ ■ Strong Performer, Getting Expensive [ⓘ](#) [In 1 Starfolio Basket](#)

[Download real time STOCK REPORT](#)

2177.90 -18.00 (-0.82%) ↑ Near 52W High of ₹2226.30

1.0M NSE+BSE Volume
NSE 16 Jan, 2026 3:31 PM (IST)

[Watchlist](#) [Portfolio](#) [Alert](#) [My Notes](#) [TRADE STOCK](#)

Overview FORECASTER STOCK REPORT Buy Sell Zone F&O Financials News Reports Technicals Shareholding Deals Corporate Actions Alerts About

Lupin - LUPIN - stock price prediction, stock forecast, target price, analyst ratings from 37 analysts

Lupin has a share price target of Rs 2302, revenue growth forecast of 14.6%, and profit growth estimate of 37.3% for FY26, based on top 37 analyst calls.

Lupin FORECASTER - Analyst Estimates [ⓘ](#)

[FORECASTER DASHBOARD →](#)

